Current role
Helen Collins
Personal wealth note: Equibles reports source-backed professional activity and disclosed compensation; it does not estimate personal net worth.
About Helen Collins
Earlier roles on record: Board Member at IO Biotech, Inc. (IOBTQ) until March 31, 2026. IO Biotech, Inc. reported in an 8-K filed March 31, 2026 that Helen Collins resigned as Board of Directors, effective March 31, 2026. Enliven Therapeutics, Inc. reported in an 8-K filed March 1, 2023 that Helen Collins was appointed Chief Medical Officer, effective February 23, 2023. The proxy statement of Enliven Therapeutics, Inc. reports total compensation of $3,501,699 for Helen Collins in fiscal 2025, including a base salary of $523,000. Disclosed compensation is on record for 4 fiscal years.
“Concurrently with the Petition, on March 31, 2026, each member of the Company's board of directors, Peter Hirth, Helen Collins, Christian Elling, Kathleen Glaub, Heidi Hunter and David Smith, resigned from the Board of Directors of the Company and all of its committees.”
“In connection with and effective as of the closing of the Merger, on February 23, 2023, the Company entered into a confirmatory employment letter with Messrs. Kintz and Hohl and Dr. Helen Collins, who was appointed as the Company’s Chief Medical Officer in connection with the Merger.”
Summary generated from SEC filings and earnings-call records held by Equibles.
Affiliation history
Recorded current and former roles; source labels appear when available.
-
Enliven Therapeutics, Inc. (ELVN)
Proxy statement
CurrentStart not stated–present
-
2023-01-01–2026-03-31
Company network
Recorded roles and call appearances connecting this person to public companies.
Leadership on record at Enliven Therapeutics, Inc.
Other people whose current roles at this company are on record from its filings.
- Richard Fair CEO, Board Member
- Rick Fair CEO, Board Member
- Sam Kintz, M.B.A. CEO, Board Member
- Samuel Kintz CEO
- Richard Heyman, Ph.D. Chairman, Board Member
- Ben Hohl CFO
- Benjamin Hohl CFO
- Anish Patel COO
- Andrew Phillips, Ph.D. Board Member
- Continuing Directors Board Member
Executive compensation
Compensation components disclosed in company proxy statements. Amounts are nominal USD; total is the company-reported figure.
| Fiscal year | Company | Role | Salary | Total |
|---|---|---|---|---|
| 2025 | Enliven Therapeutics, Inc. (ELVN) | Chief Medical Officer | $523,000 | $3,501,699 |
| 2024 | Enliven Therapeutics, Inc. (ELVN) | Chief Medical Officer | $495,000 | $2,771,410 |
| 2023 | Enliven Therapeutics, Inc. (ELVN) | Chief Medical Officer | $479,011 | $4,064,258 |
| 2022 | Enliven Therapeutics, Inc. (ELVN) | Chief Medical Officer | $400,000 | $645,504 |
Recent activity
Earnings-call and investor-event appearances, plus filed executive appointments or departures, newest first.